Details

Project TitleEnhanced Gene Silencing by RNAi
Track Code2005-063
Short Description

Novel strategy to improve gene silencing by RNAi  for development of therapeutics

#therapeutics #genetherapy #RNA #researchtool #method

Abstract

RNAi has been proposed as a therapeutic strategy for disorders characterized by aberrant gene overexpression (cancer, macular degeneration etc.) as well as for controlling viral infections. However, the main roadblock for using RNAi technology as a therapeutic is that several human proteins normally inhibit this process, lowering the efficiency of gene silencing. Northwestern researchers have devised a method for identification of these proteins and have identified several endogenous RNAi inhibitory proteins. Prof. Carthew and colleagues are conducting experiments to strategically inhibit these proteins in order to enhance RNAi efficiency. By identifying and disabling RNAi inhibiting host proteins, RNAi could evolve into an effective treatment for various diseases. The search for RNAi inhibitory proteins has also been undertaken in animal cells, suggesting that this approach could enable improvements in production of genetically modified organisms for research purposes.

 
TagsRESEARCH TOOL: gene, RESEARCH TOOL: method, THERAPEUTICS: RNA, THERAPEUTICS: gene therapy
 
Posted DateMay 5, 2015 1:29 PM

Inventor(s)

Richard Carthew*

Dinari Harris

Young Sik Lee

Applications

  • Gene therapy for infectious or chronic diseases
  • Rational drug design
  • RNAi laboratory research

Advantages

  • Improved RNAi efficiency
  • Applicable to a wide range of host cells

Publications

IP Status

US patents 8,318,688 and 8,735,371 have been issued.

International patent application has been filed.

Contact Information

Michael Moore, PhD

Invention Manager

(p) 847.491.4645

(e) michaelmoore@northwestern.edu